Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II Study of Recombinant 9-valent HPV Vaccine in Healthy Females
CTR20192644Phase 2Completed
- Sponsor
- Beijing Konruns Pharmaceutical Co., Ltd.
- Start
- Jan 2020
- Modality
- Split/Subunit Vaccines → Inactivated Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, Recombinant Protein Vaccines → Recombinant Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of recombinant human papillomavirus 9-valent vaccine in human papillomavirus infection, Cervical Cancer (CC), vaginal cancer, Vulval carcinoma, anal cancer, sponsored by Beijing Konruns Pharmaceutical Co., Ltd.. Started Jan 2020; status: completed.
02
Drugs
recombinant human papillomavirus 9-valent vaccine
03
Conditions
human papillomavirus infectionCervical Cancer (CC)vaginal cancerVulval carcinomaanal cancer
Beyond the preview
Go deeper on CTR20192644.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20192644.